Chugai Pharmaceutical
Chugai Pharmaceutical is an R&D-oriented pharmaceutical company with strengths in its unique drug discovery technology platform, including antibody engineering technology.
Launch date
Employees
Market cap
$85.2b
Enterprise valuation
$78.8b (Public information from Sep 2024)
Share price
JPY6877 4519.T
Tokyo Japan (HQ)
Financials
Estimates*
| JPY | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 786.9b | 999.8b | 1.3t | 1.1t | 1.1t | 1.2t | 1.2t |
| % growth | 15 % | 27 % | 26 % | (12 %) | 1 % | 3 % | 5 % |
| EBITDA | 298.3b | 419.4b | 531.2b | 443.8b | 531.0b | 538.5b | 570.2b |
| % EBITDA margin | 38 % | 42 % | 42 % | 40 % | 48 % | 47 % | 47 % |
| Profit | 214.7b | 303.0b | 374.4b | 325.5b | 365.5b | 384.0b | 415.6b |
| % profit margin | 27 % | 30 % | 30 % | 29 % | 33 % | 33 % | 34 % |
| EV / revenue | 11.0x | 5.7x | 4.0x | 7.2x | 10.1x | 9.6x | 9.0x |
| EV / EBITDA | 29.1x | 13.5x | 9.5x | 18.1x | 21.2x | 20.6x | 19.1x |
| R&D budget | 117.9b | 137.3b | 149.6b | 174.9b | - | - | - |
| R&D % of revenue | 15 % | 14 % | 12 % | 16 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
| Total Funding | - | ||
Recent News about Chugai Pharmaceutical
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
